Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].

Zhonghua yi xue za zhi - 28 Dec 2005

Zhao Min, Xiao Shao-wen, Yang Jing-xian, Zhang Shan-wen, Lü You-yong

Abstract excerpt

OBJECTIVE: To determine the alteration of p53 gene in tumor tissues and to monitor the immunoresponsiveness to anti adenovirus in patients following treatment of recombinant adenovirus-p53 (Adp53, SBN-1) combined with radiation. METHODS: Tumor tissues were collected from 22 patients with malignant tumors at advanced stage before and after treatment with recombinant adenovirus-p53 (Adp53, SBN-1) combined with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Antibodies
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Genetic Therapy

Share to Immunoglobulin G

Share to Immunoglobulin M

Share to Radiotherapy

Source

Identifiers

PMID: 16686067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].PMID 16686067Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Semantic proximity Read ↗

Adenovirus p53 gene therapySemantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Semantic proximity Read ↗

[p53 as a molecular target for cancer therapy].Semantic proximity Read ↗

[Clinical significance of p53 antibody].Semantic proximity Read ↗

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read ↗

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.Semantic proximity Read ↗

Adenoviral gene therapy in head and neck cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.